quisinostat quisinostat quisinostat (usan; development code jnj-26481585) is an experimental drug candidate for the treatment of cancer. it is a "second generation" histone deacetylase inhibitor with antineoplastic activity. it is highly potent against class i and ii hdacs. quisinostatclinical dataother namesjnj-26481585atc codenonepharmacokinetic databioavailabilityoralidentifiers iupac name n-hydroxy-2-amino}methyl)-1-piperidinyl]-5-pyrimidinecarboxamide cas number875320-29-9 ypubchem cid11538455chemspider9713236unii9bj85k1j8skeggd10321comptox dashboard (epa)dtxsid90236376 chemical and physical dataformulac21h26n6o2molar mass394.479 g·mol−13d model (jsmol)interactive image smiles o=c(no)c1cnc(nc1)n2ccc(cc2)cncc4c3ccccc3n(c4)c inchi inchi=1s/c21h26n6o2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29h,6-11h2,1h3,(h,25,28)key:pawiyayfnxqgap-uhfffaoysa-n history it was developed by janssen pharmaceuticals and licensed to newvac llc. preclinical studies show that quisinostat amplifies hdac-repressed expression of e-cadherin, leading to a reversal of epithelial to mesenchymal transition in tumor cells. clinical trials results of a phase i trials in patients with multiple myeloma in combination with bortezomib and dexamethasone were published in 2016.